Beta
Alvimopan
medication Under reviewA peripherally acting mu-opioid receptor antagonist used to accelerate gastrointestinal recovery after bowel resection surgery.
Research summary
Human studies in healthy volunteers show that alvimopan can reverse opioid-induced delays in gastrointestinal transit and accelerate colonic transit, while not significantly affecting centrally mediated opioid effects such as analgesia or pupillary constriction. Pharmacokinetic studies in healthy subjects also show measurable oral absorption and predictable exposure across dose ranges studied. Overall, the evidence base in healthy humans supports a clear physiologic effect on opioid-slowed gut motility, but not broad health or performance benefits. The strongest clinical evidence for therapeutic benefit comes from surgical populations rather than healthy adults, so for healthy people this remains primarily a mechanistic research compound rather than a general supplement.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Alvimopan to your stack to report effects
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
[Authors not shown in search result]
ENTEREG label: clinical pharmacology and cardiac conduction data in healthy volunteers
U.S. Food and Drug Administration
Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study.
Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC
No reports yet
Be the first to report this effect and help the community.
Add Alvimopan to your stack to report effects
ENTEREG label: clinical pharmacology and cardiac conduction data in healthy volunteers
U.S. Food and Drug Administration
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
[Authors not shown in search result]
Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study.
Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC
No reports yet
Be the first to report this effect and help the community.
Add Alvimopan to your stack to report effects
ENTEREG label: clinical pharmacology and cardiac conduction data in healthy volunteers
U.S. Food and Drug Administration
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
[Authors not shown in search result]
Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study.
Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
General digestive problems including bloating, irregular bowel movements, and discomfort
Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study.
Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
[Authors not shown in search result]
ENTEREG label: clinical pharmacology and cardiac conduction data in healthy volunteers
U.S. Food and Drug Administration
Research (3 studies)
ENTEREG label: clinical pharmacology and cardiac conduction data in healthy volunteers
U.S. Food and Drug Administration
Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study.
Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
[Authors not shown in search result]
Community updates
No updates yet for this supplement.
Be the first to share your experience!